{"id":745411,"date":"2016-03-04T10:00:00","date_gmt":"2016-03-04T10:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/"},"modified":"2025-11-07T01:25:58","modified_gmt":"2025-11-07T06:25:58","slug":"merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/","title":{"rendered":"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa"},"content":{"rendered":"<p class=\"bwalignc\">       Since 1987 Merck Has Donated More than Two Billion Treatments of        Mectizan to Help Eliminate River Blindness and Lymphatic Filariasis     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the company, together with the Mectizan Donation<br \/>\n      Program, is donating $1 million to the END Fund in support of efforts in<br \/>\n      Africa to eliminate river blindness, which is also known as<br \/>\n      onchocerciasis. Today\u2019s donation will enable participating countries to<br \/>\n      prepare for a period of post-treatment surveillance that is needed<br \/>\n      before an application can be submitted to the World Health Organization<br \/>\n      (WHO) for official elimination verification status. Efforts to eliminate<br \/>\n      river blindness are aligned with WHO\u2019s Roadmap on Neglected Tropical<br \/>\n      Diseases (NTDs), which calls for elimination of river blindness in<br \/>\n      selected countries in Africa by 2020. While three countries in Latin<br \/>\n      America have already received WHO verification of elimination of river<br \/>\n      blindness, no countries in Africa have yet achieved this goal.\n    <\/p>\n<p>\n      \u201cMerck has worked with our partners for nearly three decades to make<br \/>\n      Mectizan (ivermectin) available, free of charge, to all those afflicted<br \/>\n      by river blindness,\u201d said Kenneth C. Frazier, chairman and chief<br \/>\n      executive officer, Merck. \u201cIt is an honor to present this donation to<br \/>\n      the END Fund today alongside Dr. William Campbell, the retired Merck<br \/>\n      parasitologist who shared the 2015 Nobel Prize in Physiology or Medicine<br \/>\n      for his discoveries that led to the development of Mectizan.\u201d\n    <\/p>\n<p>\n      &#8220;The END Fund is proud to partner with Merck on this critical next step<br \/>\n      toward the end of river blindness,\u201d said Ellen Agler, CEO of the END<br \/>\n      Fund. \u201cMerck\u2019s long-standing commitment to elimination efforts is<br \/>\n      further bolstered by their thoughtful investment. Through innovative<br \/>\n      public-private partnerships coupled with country-led programs, millions<br \/>\n      of the most vulnerable people will no longer have to worry about the<br \/>\n      devastating effects of this disease. The END Fund is grateful for<br \/>\n      Merck\u2019s collaborative leadership and we look forward to others joining<br \/>\n      us, with the hope for continued momentum building towards elimination.\u201d\n    <\/p>\n<p>\n      River blindness is a parasitic infection that can cause intense itching,<br \/>\n      skin discoloration, rashes, and eye disease that often leads to<br \/>\n      permanent blindness. Common in many parts of Africa, Latin America and<br \/>\n      in Yemen, it is spread by the bites of infected black flies that breed<br \/>\n      in rapidly flowing rivers in the affected countries. Through decades of<br \/>\n      effort by a range of partners led by WHO\u2019s African Program for<br \/>\n      Onchocerciasis Control (APOC), the transmission of new cases of river<br \/>\n      blindness in Africa has been greatly reduced. In many countries it is<br \/>\n      suspected that transmission has been completely eliminated.\n    <\/p>\n<p>\n      <b>About the Mectizan Donation Program<\/b>\n    <\/p>\n<p>\n      The Mectizan Donation Program is the longest-running, disease-specific,<br \/>\n      drug-donation program and public-private partnership of its kind. In<br \/>\n      1998, Merck expanded the program to include the elimination of another<br \/>\n      disease, lymphatic filariasis. The program reaches more than 250 million<br \/>\n      people in the affected areas annually, with more than 2 billion<br \/>\n      treatments donated since 1987.\n    <\/p>\n<p>\n      <b>About the END Fund<\/b>\n    <\/p>\n<p>\n      The END Fund is the world&#8217;s first private philanthropic initiative to<br \/>\n      combat the five most common neglected tropical diseases (NTDs) that,<br \/>\n      together, cause up to 90% of the NTD burden in sub-Saharan Africa.<br \/>\n      Supported by a group of global philanthropists, the END Fund provides<br \/>\n      financing for nationwide disease control initiatives, creating new<br \/>\n      programs, supplementing existing ones, and using leveraged funds to<br \/>\n      extend and deepen the impact. The END Fund provides exceptional return<br \/>\n      on investment by harnessing the highly scalable impact of low-cost mass<br \/>\n      drug administrations. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.end.org&amp;esheet=51293798&amp;newsitemid=20160304005128&amp;lan=en-US&amp;anchor=www.end.org&amp;index=1&amp;md5=287018f22fd46676c13c3fcf9204e50d\" rel=\"nofollow\">www.end.org<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51293798&amp;newsitemid=20160304005128&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=f69669f0db9058dcccc8c060216b4896\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51293798&amp;newsitemid=20160304005128&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=f3a36c88874a1ec3291fbe0455070584\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51293798&amp;newsitemid=20160304005128&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=f6bd6c66559a54b020dfc3b8c9b0670b\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51293798&amp;newsitemid=20160304005128&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=a5b631db31862dfcb75bac844dc711ab\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51293798&amp;newsitemid=20160304005128&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=d57652616cf2a96eedff6f372d7b9074\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51293798&amp;newsitemid=20160304005128&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=018dd907c2f919c2b569b8e34f33d661\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160304005128r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       For Media:<br \/>Jennifer Allen Woodruff, 267-305-3550<br \/>or<br \/>Lainie        Keller, 908-236-5036<br \/>or<br \/>For Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Since 1987 Merck Has Donated More than Two Billion Treatments of Mectizan to Help Eliminate River Blindness and Lymphatic Filariasis Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company, together with the Mectizan Donation Program, is donating $1 million to the END Fund in support of efforts in Africa to eliminate river blindness, which is also known as onchocerciasis. Today\u2019s donation will enable participating countries to prepare for a period of post-treatment surveillance that is needed before an application can be submitted to the World Health Organization (WHO) for official elimination verification status. Efforts to eliminate river blindness are aligned with WHO\u2019s Roadmap on Neglected Tropical Diseases (NTDs), which calls for elimination of river blindness in selected countries in Africa by 2020. While three countries in Latin America have already received WHO verification of elimination of river blindness, no countries in Africa<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,54,64,289],"class_list":["post-745411","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-corporate-responsibility-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Since 1987 Merck Has Donated More than Two Billion Treatments of Mectizan to Help Eliminate River Blindness and Lymphatic Filariasis Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company, together with the Mectizan Donation Program, is donating $1 million to the END Fund in support of efforts in Africa to eliminate river blindness, which is also known as onchocerciasis. Today\u2019s donation will enable participating countries to prepare for a period of post-treatment surveillance that is needed before an application can be submitted to the World Health Organization (WHO) for official elimination verification status. Efforts to eliminate river blindness are aligned with WHO\u2019s Roadmap on Neglected Tropical Diseases (NTDs), which calls for elimination of river blindness in selected countries in Africa by 2020. While three countries in Latin America have already received WHO verification of elimination of river blindness, no countries in Africa\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\\\/\",\"name\":\"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-03-04T10:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/","og_locale":"en_US","og_type":"article","og_title":"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa - Merck.com","og_description":"Since 1987 Merck Has Donated More than Two Billion Treatments of Mectizan to Help Eliminate River Blindness and Lymphatic Filariasis Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the company, together with the Mectizan Donation Program, is donating $1 million to the END Fund in support of efforts in Africa to eliminate river blindness, which is also known as onchocerciasis. Today\u2019s donation will enable participating countries to prepare for a period of post-treatment surveillance that is needed before an application can be submitted to the World Health Organization (WHO) for official elimination verification status. Efforts to eliminate river blindness are aligned with WHO\u2019s Roadmap on Neglected Tropical Diseases (NTDs), which calls for elimination of river blindness in selected countries in Africa by 2020. While three countries in Latin America have already received WHO verification of elimination of river blindness, no countries in Africa","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:58+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/","name":"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-03-04T10:00:00+00:00","dateModified":"2025-11-07T06:25:58+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-the-mectizan-donation-program-donate-1-million-to-the-end-fund-for-efforts-to-help-eliminate-river-blindness-in-africa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d6872104-4368-46f3-9c2f-e2c27d97e62b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-the-Mectizan-Donation-Program-Donate-1-Million-to-the-END-Fund-for-Efforts-to-Help-Eliminate-River-Blindness-in-Africa-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745411\/revisions"}],"predecessor-version":[{"id":3674802,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745411\/revisions\/3674802"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745411"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}